dhes0815a
mAbexperimentalADC
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Apr 17, 2018 (NCT03451162)
Timeline
2010s
- Jan 1, 2018
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
ERBB2 inhibitor
Chemistry & pharmacology
- Multi-specific
- No
- Payload
- pyrrolobenzodiazepine
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03451162 | Phase 1 | Apr 17, 2018 | Genentech, Roche |
Showing 1 of 1 trials
Page 1 / 1